{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:40:16Z","timestamp":1789195216804,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10549-015-3599-5","type":"journal-article","created":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T17:32:20Z","timestamp":1444671140000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Paclitaxel, bevacizumab, and everolimus\/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute"],"prefix":"10.1007","volume":"154","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda D.","family":"Bosserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Harwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Priego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy W.","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"3599_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9\u201329","journal-title":"CA Cancer J Clin"},{"key":"3599_CR2","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676","journal-title":"N Engl J Med"},{"key":"3599_CR3","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239\u20133247","journal-title":"J Clin Oncol"},{"key":"3599_CR4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s12094-007-0092-6","volume":"9","author":"J Albanell","year":"2007","unstructured":"Albanell J, Dalmases A, Rovira A, Rojo F (2007) mTOR signalling in human cancer. Clin Transl Oncol 9:484\u2013493","journal-title":"Clin Transl Oncol"},{"key":"3599_CR5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671\u2013688","journal-title":"Nat Rev Drug Discov"},{"key":"3599_CR6","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","volume":"27","author":"L Zhao","year":"2008","unstructured":"Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486\u20135496","journal-title":"Oncogene"},{"key":"3599_CR7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529","journal-title":"N Engl J Med"},{"key":"3599_CR8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F, O\u2019Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580\u2013591","journal-title":"Lancet Oncol"},{"key":"3599_CR9","unstructured":"Declaration of Helsinki. www.wma.net\/e\/ethicsunit\/helsinki.htm , World Medical Association, Ethics Unit, 2007"},{"key":"3599_CR10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"E Eisenhauer","year":"2009","unstructured":"Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3599_CR11","unstructured":"Program, C.T.E. (2006). Common Terminology Criteria for Adverse Events, Version 3.0. N. DCTD, NIH, DHHS, ed. ( http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_30 ). Accessed July 2015"},{"key":"3599_CR12","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"3599_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"3599_CR14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0002-9440(10)65227-3","volume":"155","author":"A Perren","year":"1999","unstructured":"Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253\u20131260","journal-title":"Am J Pathol"},{"key":"3599_CR15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","volume":"3","author":"KE Bachman","year":"2004","unstructured":"Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772\u2013775","journal-title":"Cancer Biol Ther"},{"key":"3599_CR16","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","volume":"65","author":"LH Saal","year":"2005","unstructured":"Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554\u20132559","journal-title":"Cancer Res"},{"key":"3599_CR17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ijc.24750","volume":"126","author":"SE Ghayad","year":"2010","unstructured":"Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA (2010) Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K\/Akt signaling pathways. Int J Cancer 126:545\u2013562","journal-title":"Int J Cancer"},{"key":"3599_CR18","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMcibr043143","volume":"351","author":"PP Pandolfi","year":"2004","unstructured":"Pandolfi PP (2004) Breast cancer\u2013loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337\u20132338","journal-title":"N Engl J Med"},{"key":"3599_CR19","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","volume":"68","author":"K Stemke-Hale","year":"2008","unstructured":"Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084\u20136091","journal-title":"Cancer Res"},{"key":"3599_CR20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ijc.24831","volume":"126","author":"E Lopez-Knowles","year":"2010","unstructured":"Lopez-Knowles E, O\u2019Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126:1121\u20131131","journal-title":"Int J Cancer"},{"key":"3599_CR21","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Andre F, Jiang Z, et al: Phase 3, randomized, double-blind, placebo- controlled mutlicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first- line therapy in women with HER2+ advanced breast cancer: BOLERO-1. San Antonio Breast Cancer Symposium, 2014, Abstract # S6-01","DOI":"10.1158\/1538-7445.SABCS14-S6-01"},{"key":"3599_CR22","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","volume":"27","author":"F Meric-Bernstam","year":"2009","unstructured":"Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278\u20132287","journal-title":"J Clin Oncol"},{"key":"3599_CR23","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1074\/jbc.M010840200","volume":"276","author":"RA Campbell","year":"2001","unstructured":"Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817\u20139824","journal-title":"J Biol Chem"},{"key":"3599_CR24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/35035131","volume":"407","author":"T Simoncini","year":"2000","unstructured":"Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538\u2013541","journal-title":"Nature"},{"key":"3599_CR25","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","volume":"10","author":"LA deGraffenried","year":"2004","unstructured":"deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059\u20138067","journal-title":"Clin Cancer Res"},{"key":"3599_CR26","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/bcr2594","volume":"12","author":"CJ Creighton","year":"2010","unstructured":"Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG et al (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12:R40","journal-title":"Breast Cancer Res"},{"key":"3599_CR27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P et al (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:195\u2013202","journal-title":"J Clin Oncol"},{"key":"3599_CR28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1078-0432.CCR-10-1133","volume":"17","author":"J Dupont Jensen","year":"2011","unstructured":"Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Gardner H (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17:667\u2013677","journal-title":"Clin Cancer Res"},{"key":"3599_CR29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","volume":"10","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10:1093\u20131101","journal-title":"Mol Cancer Ther"},{"key":"3599_CR30","first-page":"S1","volume":"70","author":"T Bachelot","year":"2011","unstructured":"Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, Eymard J-C, Debled M, Spaeth D et al (2011) Abstract S1-6: TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 70:S1\u2013S6","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3599-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3599-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T07:23:32Z","timestamp":1567236212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3599-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3599-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}